Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Talpaz

Showing results (51-60 of 350) with videos related to

Pageof 35
Sort By:
Leukemia & Lymphoma|September 1, 1992
The modulatory hematopoietic activities of leukemia inhibitory factorZ Estrov, M Talpaz, M Wetzler, et al.
Leukemia & Lymphoma|January 1, 1993
CML: mechanisms of disease initiation and progressionM Wetzler, M Talpaz, Z Estrov, et al.
Cancer Surveys|January 1, 1989
Therapy of chronic myelogenous leukaemia with interferonsM Talpaz, R Kurzrock, H Kantarjian, et al.
Hematologic Pathology|January 1, 1988
Chronic myelogenous leukemia--past, present, and futureH M Kantarjian, M Talpaz, J U Gutterman
Cancer Research|April 6, 2001
The BCR gene and philadelphia chromosome-positive leukemogenesisE Laurent, M Talpaz, H Kantarjian, et al.
Cancer Investigation|January 1, 1995
Treatment of neurotoxic side effects of interferon-alpha with naltrexoneA D Valentine, C A Meyers, M Talpaz
Stem Cells (Dayton, Ohio)|March 1, 1993
Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesisA Ferrajoli, M Talpaz, R Kurzrock, et al.
Cancer|December 1, 1983
Rheumatoid factors in the sera of patient with gastrointestinal carcinomaA Schattner, A Shani, M Talpaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativityR Kurzrock, Z Estrov, H Kantarjian, et al.
International Journal of Cancer|July 15, 1985
Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN alpha) therapyB L Maxwell, M Talpaz, J U Gutterman
Pageof 35

Showing results (51-60 of 350) with videos related to

Sort By:
Pageof 35
Leukemia & Lymphoma|September 1, 1992
The modulatory hematopoietic activities of leukemia inhibitory factorZ Estrov, M Talpaz, M Wetzler, et al.
Leukemia & Lymphoma|January 1, 1993
CML: mechanisms of disease initiation and progressionM Wetzler, M Talpaz, Z Estrov, et al.
Cancer Surveys|January 1, 1989
Therapy of chronic myelogenous leukaemia with interferonsM Talpaz, R Kurzrock, H Kantarjian, et al.
Hematologic Pathology|January 1, 1988
Chronic myelogenous leukemia--past, present, and futureH M Kantarjian, M Talpaz, J U Gutterman
Cancer Research|April 6, 2001
The BCR gene and philadelphia chromosome-positive leukemogenesisE Laurent, M Talpaz, H Kantarjian, et al.
Cancer Investigation|January 1, 1995
Treatment of neurotoxic side effects of interferon-alpha with naltrexoneA D Valentine, C A Meyers, M Talpaz
Stem Cells (Dayton, Ohio)|March 1, 1993
Analysis of the effects of tumor necrosis factor inhibitors on human hematopoiesisA Ferrajoli, M Talpaz, R Kurzrock, et al.
Cancer|December 1, 1983
Rheumatoid factors in the sera of patient with gastrointestinal carcinomaA Schattner, A Shani, M Talpaz, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 29, 1998
Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativityR Kurzrock, Z Estrov, H Kantarjian, et al.
International Journal of Cancer|July 15, 1985
Down-regulation of peripheral blood cell interferon receptors in chronic myelogenous leukemia patients undergoing human interferon (HuIFN alpha) therapyB L Maxwell, M Talpaz, J U Gutterman
Pageof 35